ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2015; 6(4):387-393. doi:10.7150/jca.11316 This issue Cite
Research Paper
Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis
1. Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 150-950, Republic of Korea
2. Department of Radiology, Dongtan Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Hwasung 445-907, Republic of Korea
3. Department of Internal Medicine, Dongtan Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Hwasung 445-907, Republic of Korea
4. Department of Surgery, Hallym University Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Anyang 431-070, Republic of Korea
* Jung Han Kim and Seon Jeong Min equally contributed as to this study.
Citation:
Kim JH, Min SJ, Jang HJ, Cho JW, Kim SH, Kim HS. Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis. J Cancer 2015; 6(4):387-393. doi:10.7150/jca.11316. https://www.jcancer.org/v06p0387.htm
Other stylesAbstract
Background: We conducted this pooled analysis to investigate the impact of RECIST 1.1 on the selection of target lesions and classification of tumor response, in comparison with RECIST 1.0.
Methods: We searched MEDLINE and EMBASE for articles with terms of RECIST 1.0 or RECIST 1.1. We looked into all abstracts and virtual meeting presentations from the conferences of ASCO and ESMO between 2009 and 2013.
Results: There were six articles in the literature comparing the clinical impacts of RECIST 1.0 and RECIST 1.1 in patients with metastatic cancer. A total of 359 patients were recruited from the six trials; 217 with non-small cell lung cancer, 61 with gastric cancer, 58 with colorectal cancer, and 23 with thyroid cancer. The number of target lesions by RECIST 1.1 was significantly lower than that by RECIST 1.0 (P<0.001). Because of new lymph node criteria, fourteen patients (3.1%) had no target lesions when adopting RECIST 1.1. RECIST 1.1 showed high concordance with RECIST 1.0 in the assessment of tumor responses (k = 0.903). Sixteen patients (4.8%) showed disagreement between the two criteria.
Conclusion: This pooled study demonstrated that RECIST 1.1 showed a highly concordant response assessment with RECIST 1.0 in patients with metastatic cancer.
Keywords: RECIST 1.0, RECIST 1.1, Target lesion, Tumor response
Citation styles
APA
Kim, J.H., Min, S.J., Jang, H.J., Cho, J.W., Kim, S.H., Kim, H.S. (2015). Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis. Journal of Cancer, 6(4), 387-393. https://doi.org/10.7150/jca.11316.
ACS
Kim, J.H.; Min, S.J.; Jang, H.J.; Cho, J.W.; Kim, S.H.; Kim, H.S. Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis. J. Cancer 2015, 6 (4), 387-393. DOI: 10.7150/jca.11316.
NLM
Kim JH, Min SJ, Jang HJ, Cho JW, Kim SH, Kim HS. Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis. J Cancer 2015; 6(4):387-393. doi:10.7150/jca.11316. https://www.jcancer.org/v06p0387.htm
CSE
Kim JH, Min SJ, Jang HJ, Cho JW, Kim SH, Kim HS. 2015. Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis. J Cancer. 6(4):387-393.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.